Polyrizon Ltd. (PLRZ)

Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform

Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker

Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement

Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement

Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment